Efficacy of Oral Antibiotics for Non-Severe Exacerbations of Bronchiectasis in Children (BEST 1): A Multi-Centre, Double-Blind, Double-Dummy, Randomised Placebo-Controlled Trial
File version
Author(s)
Grimwood, Keith
Ware, Robert S
Byrnes, Catherine
Morris, Peter S
Masters, I Brent
McCallum, Gabrielle B
Binks, Michael J
Smith-Vaughan, Heidi
O’Grady, Kerry-Ann F
Champion, Anita
Buntain, Helen M
Schultz, Andr eacute
Chatfield, Mark
Torzillo, Paul J
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Background: Bronchiectasis guidelines recommend antibiotics for treating acute respiratory exacerbations, but placebo-controlled, randomised-controlled trials (RCTs) are lacking in children. Since many exacerbations are virus-triggered, antibiotics may be unnecessary for non-severe (non-hospitalised) episodes. We hypothesised that oral amoxicillin-clavulanate and azithromycin are both superior to placebo for achieving symptom resolution by day-14 when treating non-severe exacerbations in children.
Journal Title
The Lancet
Conference Title
Book Title
Edition
Volume
Issue
9
Thesis Type
Degree Program
School
Publisher link
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Biomedical and clinical sciences
Clinical sciences
Health sciences
Persistent link to this record
Citation
Goyal, V; Grimwood, K; Ware, RS; Byrnes, C; Morris, PS; Masters, IB; McCallum, GB; Binks, MJ; Smith-Vaughan, H; O’Grady, K-AF; Champion, A; Buntain, HM; Schultz, AE; Chatfield, M; Torzillo, PJ; Chang, AB, Efficacy of Oral Antibiotics for Non-Severe Exacerbations of Bronchiectasis in Children (BEST 1): A Multi-Centre, Double-Blind, Double-Dummy, Randomised Placebo-Controlled Trial, The Lancet, 2019, (9)